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 Abstract
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The median survival of patients with HER2-positive metastatic breast cancer has more than doubled since the discovery of
HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in
2017.  The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the 1st line, followed by the
addition of lapatinib and by a switch to another cytotoxic agent after progression.  Results of CLEOPATRA, EMILIA and TH3RESA trials
have changed this clinical practice.  The current consensus includes horizontal dual blockade (trastuzumab+pertuzumab) with
taxanes or vinorelbine in the 1st line, followed by trastuzumab-emtansine (T-DM1) in the 2nd line, with addition of lapatinib in the
later lines of treatment.  However, the fast and simultaneous development of new drugs led to a relative shortage of clinical
evidence to support this sequence.  Triple-positive breast cancers (TPBC), which express both hormonal receptors and HER2,
constitute nearly half of HER2-positive cases.  For these tumours, the current consensus is to add endocrine therapy after
completion of cytotoxic treatment.  Again, this consensus is not fully evidence-based.  In view of the recent progress in treatment
of oestrogen-receptor-positive breast cancers, a series of trials is evaluating addition of CDK4/6 inhibitors, aromatase inhibitors
or fulvestrant to HER2-targeted and cytotoxic chemotherapy in TPBC patients.  Despite the remarkable progress in treatment of
HER2-positive breast cancer, metastatic disease is still incurable in the majority of patients.  A wide range of novel therapies are
under development to prevent and overcome resistance to current HER2-targeted agents.  This review discusses pivotal clinical
trials that have shaped current clinical practices, the current consensus recommendations and the new experimental treatments
in metastatic HER2-positive breast cancer.
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Abstract 
The median survival of patients with HER2-positive metastatic breast cancer has more than doubled 
since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior 
introduction of trastuzumab) to more than 4 years in 2017.  The initial generation of HER2-targeted 
therapies included trastuzumab with taxanes in the 1st line, followed by the addition of lapatinib and 
by a switch to another cytotoxic agent after progression.  Results of CLEOPATRA, EMILIA and 
TH3RESA trials have changed this clinical practice.  The current consensus includes horizontal dual 
blockade (trastuzumab+pertuzumab) with taxanes or vinorelbine in the 1st line, followed by 
trastuzumab-emtansine (T-DM1) in the 2nd line, with addition of lapatinib in the later lines of 
treatment.  However, the fast and simultaneous development of new drugs led to a relative 
shortage of clinical evidence to support this sequence.  Triple-positive breast cancers (TPBC), which 
express both hormonal receptors and HER2, constitute nearly half of HER2-positive cases.  For these 
tumours, the current consensus is to add endocrine therapy after completion of cytotoxic treatment.  
Again, this consensus is not fully evidence-based.  In view of the recent progress in treatment of 
oestrogen-receptor-positive breast cancers, a series of trials is evaluating addition of CDK4/6 
inhibitors, aromatase inhibitors or fulvestrant to HER2-targeted and cytotoxic chemotherapy in TPBC 
patients.  Despite the remarkable progress in treatment of HER2-positive breast cancer, metastatic 
disease is still incurable in the majority of patients.  A wide range of novel therapies are under 
development to prevent and overcome resistance to current HER2-targeted agents.  This review 
discusses pivotal clinical trials that have shaped current clinical practices, the current consensus 
recommendations and the new experimental treatments in metastatic HER2-positive breast cancer. 
Keywords 
HER2, HER2-positive breast cancer, triple positive breast cancer, metastatic breast cancer, 
trastuzumab, pertuzumab, lapatinib, trastuzumab-emtansine, metastatic, breast cancer, therapies 
Abbreviations 
HER2 (1,3,4): Human Epidermal growth factor Receptor 2 (1,3,4), EGFR: human Epidermal Growth 
Factor Receptor (same as HER1), ERBB: human epidermal growth factor receptors family (same as 
HER family; historically named after erbB gene of avian erythroblastosis virus), BC: Breast Cancer, 
MBC: Metastatic Breast Cancer, EBC: Early Breast Cancer, TPBC: Triple Positive Breast Cancer, PFS: 
median Progression-Free Survival, OS: median Overall Survival, ORR: Objective Response Rate, BM: 
Brain Metastases, BBB: Blood Brain Barrier, AI: Aromatase Inhibitor, ER: oEstrogen Receptor, NK: 
Natural Killer cells, ADC: Antibody-Drug Conjugate, TKI: Tyrosine Kinase Inhibitor 
1. Introduction 
HER2 was discovered as a human proto-oncogene in 1985 through its homology with an avian viral 
oncogene v-erbB and with the human EGFR gene.  In 1987 D. Slamon with co-authors described 
amplification of HER2 in ~30% of clinical samples of breast cancers along with its association with 
aggressive disease and poor survival (1).  Trastuzumab, the first HER2-targeted drug, was 
successfully tested in 2001 (2).  Trastuzumab’s success triggered development of other HER2-
targeted agents, including new antibodies (pertuzumab), kinase-inhibitors (lapatinib, neratinib) and 
antibody-conjugated drugs (trastuzumab-emtanasine).  Numerous trials were conducted to select 
optimal combinations of HER2-targeting agents with cytotoxic therapies.  As a result, HER2-positive 
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breast cancer patients now have one of the best survival rates if targeted treatments are applied (3-
6).   
HER2 is a member of ERBB family of membrane tyrosine-kinase receptors, which also include EGFR, 
HER3 and HER4 (Fig 1A).  The generic structure of an ERBB receptor includes extra-cellular ligand-
binding domains and an intra-cellular kinase domain.  ERBB receptors are activated by a number of 
peptide ligands including EGF, TGF-alpha, amphiregulin (for EGFR) and neuregulins (for HER3 and 
HER4).  Ligand binding causes receptor dimerization, activation of the kinase domains, auto-
phosphorylation and initiation of down-stream signalling.  This generic scheme has two exceptions: 
HER3 contains no kinase domain and HER2 has no known ligand. Thus, HER2 and HER3 rely on 
hetero-dimerization with other ERBB receptors to initiate their cellular effects.  The key pathways 
downstream of HER2 include PI3K and MAPK signalling (Fig 1B) (7, 8).  MAPK cascade includes 
sequential activation of RAS-RAF-MEK-ERK, which may stimulate proliferation through increased 
synthesis of CCND1 mediated by MYC and JUN/FOS transcription factors (9).  The PI3K pathway 
starts with phosphorylation of PIP2 to PIP3, followed by activation of AKT.  The de-phosphorylation 
of PIP3 to PIP2 is catalysed by PTEN.  The effect of PI3K-AKT signalling on proliferation may be 
mediated by inactivation of the p27 cell cycle inhibitor (10).  Upon phosphorylation by AKT, p27 
moves from the nucleus to the cytoplasm, thus allowing activation of CCNE1-CDK2 by CCND1-
CDK4/6 and promoting G1-to-S cell cycle transition.  Along with the effects on cell proliferation, 
PI3K-AKT signalling stimulates protein biosynthesis and inhibits apoptosis (11).  Taken together, such 
downstream signalling explains the oncogenic effect of HER2 amplification in breast cancer.   
2. Drugs used for treatment of HER2-positive metastatic breast 
cancer 
Current medical treatment of HER2-positive metastatic breast cancer (MBC) combines HER2-
targeted agents with cytotoxic and hormonal therapies.   
2.1. HER2-targeted agents 
The HER2-targeted agents currently approved for treatment of MBC include trastuzumab, 
pertuzumab, lapatinib and trastuzumab-emtansine.   
2.1.1. Trastuzumab 
Trastuzumab (Herceptin) is a humanised monoclonal antibody binding to the extracellular portion of 
HER2 close to its transmembrane domain (Fig 1A) (12).  It was the first HER2-targeted agent 
introduced to breast cancer clinics (2) and it remains a key component of the most effective 
regimens used to treat HER2+ve breast cancers now (13-15).  Being an anti-HER2 antibody, 
trastuzumab has two main mechanisms of action: (i) it suppresses HER2 signalling and (ii) it triggers 
an antibody-mediated immune response.  Studies on cell lines allowed exploration of the effect on 
the signalling without interference with immune-mediated mechanisms.  It was shown that 
trastuzumab may inhibit HER2 signalling either by destabilising HER2 heterodimers (12) or by causing 
internalisation of HER2 receptors with subsequent lysosomal degradation (16).  In addition, 
trastuzumab inhibits HER2 signalling by preventing cleavage of HER2 extracellular domain (17): the 
cleavage of HER2 ectodomain would create a functionally active truncated isoform of HER2 (p95-
HER2) (18), which contributes to the tumours progression (19). It was also suggested that 
trastuzumab may inhibit HER2-cSRC interaction, resulting in the activation of PTEN that attenuates 
PI3K-AKT signalling (20).  Importantly, trastuzumab has no clinical effect on HER2-negative tumours 
(21).  Therefore, all its clinically relevant effects are mediated through HER2.   
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The contribution of immune mechanisms to the trastuzumab response was confirmed by preclinical 
and clinical studies of Fc-gamma receptors, involved in the cell-mediated immune response.  Thus, 
trastuzumab effect on HER2-positive xenografts depends on function of Fc-gamma receptors (22) 
and genetic polymorphisms of Fc-gamma receptors are associated with clinical response to 
trastuzumab (23).  At the same time, it was noted that the contribution of immune mechanisms may 
be compromised by immunosuppression when trastuzumab is combined with cytotoxic agents (24).  
Patent protection of Genentech’s trastuzumab (branded as Herceptin) expired in 2014 in Europe 
and it will expire in 2019 in the US.  In 2013, a generic drug MYL-1401O with a protein sequence 
identical to Herceptin was manufactured by Mylan.  After a phase III trial, which confirmed its clinical 
equivalency to Herceptin (25) in 2017, MYL-1401O (branded as Ogivri, trastuzumab-dkst) was 
approved by FDA as a biosimilar to Herceptin in the US.  A number of other trastuzumab biosimilars 
have been approved in other countries.   
Finally, a recent series of clinical trials demonstrated that trastuzumab can be administered 
subcutaneously, instead of conventional intravenous administration.  This makes trastuzumab 
treatment more convenient for patients and reduces associated health care costs (26), especially in 
metastatic settings where trastuzumab is administered to fragile patients and treatment may last for 
several years.   
2.1.2. Pertuzumab 
Pertuzumab is another monoclonal anti-HER2 antibody.  It binds HER2 at a different location than 
trastuzumab (Fig 1A), primarily preventing formation of HER2-HER3 heterodimers (27). Pertuzumab 
was initially found to be effective in combination with trastuzumab (so-called “horizontal dual-
blockade”) (28-30).  Later, in a smaller study, pertuzumab was tested as a monotherapy; however, it 
showed much less efficiency than the combination (31).  HER2-HER3 heterodimer is the most potent 
HER2 heterodimer, and combination of trastuzumab with pertuzumab is currently the most potent 
combination of HER2-targeted agents (as shown in CLEOPATRA trial (32) discussed in more details 
later).  
2.1.3. Lapatinib 
Lapatinib is a small-molecule tyrosine-kinase inhibitor (TKI) targeting intracellular domains of HER2 
and EGFR (Fig 1A).  While it showed clinical activity in HER2-positive MBC (33, 34), it is more toxic 
and less active than trastuzumab (35).  Thus, lapatinib is reserved for use as an addition to 
trastuzumab (so-called “vertical dual-blockade”(30)) in later lines of treatment in patients who 
cannot tolerate cytotoxic chemotherapy (36, 37) or with brain metastases (as discussed in more 
details in section 5.2) (36, 38).   
2.1.4. Trastuzumab-emtansine, T-DM1 
Trastuzumab-emtansine (also known as T-DM1 or Kadcyla) is an antibody-drug conjugate (ADC).  
This new class of drugs allows for targeted delivery of cytotoxic molecules to the tumour, potentially 
increasing their efficiency and reducing their toxicity at the same time (39).  T-DM1 consists of a 
highly potent mitotic poison maytansine (DM1) linked to trastuzumab (40).  Upon binding with HER2 
on tumour cells surface the drug is internalised, maytansine is released from the complex and 
inhibits microtubule polymerisation.  Tested in clinic in the 1970s, maytansine displayed an 
unacceptably high toxicity without the targeted delivery (41).  However, trastuzumab-delivered 
maytansine (T-DM1) showed a good safety profile, causing fewer serious adverse effects (grade 3 or 
worse) than most of other treatment regimens in HER2+ve breast cancer (42-45).  A series of phase-
III trials showed high clinical efficacy T-DM1 in HER2-positive MBC (MARIANNE, EMILIA and TH3RESA 
– see Fig 2 and section 3.3).  T-DM1 is superior to other current HER2-targeting therapies in the 2nd 
In r vi
ew
  Page 5 of 30 
and later lines in patients pre-treated with trastuzumab or lapatinib (45, 46).  In 1st line treatment, T-
DM1 is non-inferior to the combination of trastuzumab and taxane, while showing better tolerability 
(42).  T-DM1 is also being tested in combination with pertuzumab and taxanes (47).   
2.2. Cytotoxic component 
Trastuzumab shows some activity as a monotherapy in HER2-positive MBC (48).  However, early 
addition of cytotoxic chemotherapy to trastuzumab markedly improves both the response rates and 
the overall survival of MBC patients (see Section 3.1 and Fig 2: Inoue 2010 and HERTAX trials) (49, 
50).  These clinical data are in agreement with the preclinical models, which showed synergistic and 
additive interactions of trastuzumab with chemotherapeutic agents used in BC (including platinum 
agents, taxanes and anthracyclines) (51).  It was suggested that the synergy of trastuzumab with 
DNA-damaging chemotherapy, such as cross-linking platinum agents, may be explained by the 
inhibition of HER2-stimulated DNA-repair genes (52).  Mechanism of the synergy with taxanes is less 
clear.  However, it was hypothesised (53) that this may be mediated by inhibition of survivin 
expression (54, 55), which is involved in microtubule stabilisation during mitosis (56).   
A single cytotoxic agent is typically added to HER2-targeted treatment.  Use of anthracyclines in 
HER2+ve MBC is limited because many patients were exposed to anthracyclines in the adjuvant 
setting, and because of the cumulative cardiotoxicity of anthracyclines.  Importantly, the 
anthracyclines cardiotoxicity overlaps with the toxicity of trastuzumab leading to high rates of heart 
failure with this combination (57).  The cardiotoxicity is substantially reduced if HER2-targeted 
agents are combined with taxanes instead of anthracyclines.  This made taxanes the treatment of 
choice for the cytotoxic component in the 1st line treatment of HER2-positive MBC (e.g. see the 1st 
line trials on Fig 2) (58). The most common taxane regimens include weekly paclitaxel, or docetaxel 
administered at 3 weeks intervals.  Nab-paclitaxel may be considered for patients that do not 
tolerate other taxanes or steroid premedication (e.g. for diabetic patients).  Vinorelbine is 
considered as an alternative to taxanes since it showed similar efficacy and better tolerability in 1st 
line HERNATA and VELVET trials (59, 60).  Attempts of adding a second cytotoxic agent, e.g. 
combining trastuzumab + taxanes with capecitabine (CHAT trial) or with a platinum salt (BCIRG 007 
trial) improved response rates at the expense of higher toxicity.  Importantly, the addition of a 
second cytotoxic agent have provided no survival benefit in these trials (61, 62).   
There is no strong evidence to select a cytotoxic agent after taxanes.  Capecitabine is a convenient 
oral therapy.  Its combination with HER2-targetd agents showed satisfactory clinical efficiency (63-
65) and it is frequently used in 2nd-line clinical trials (Fig 2).  The 3rd line cytotoxic component may 
include vinorelbine, if not used earlier.  At later lines, the most common physician choices include 
gemcitabine and eribulin (45), allowing the change of cytotoxic agents along several lines of 
metastatic treatment.   
2.3. Hormonal component 
At least 50% of HER2+ve tumours express hormonal receptors (66).  This group of “triple-positive” 
breast cancers (TPBC) have distinct biology and clinical features (67, 68).  Current approaches to 
treatment of metastatic TPBC will be discussed in more details in section 5.1.  However, combining 
HER2-targeted and cytotoxic agents with endocrine therapies is one of the obvious options for this 
group of patients (14, 69).  It has previously been shown that the addition of HER2-targeting to 
endocrine treatment improves outcomes in metastatic TPBC (see TAnDEM and EGF30008 trials on 
Fig 3) (70, 71).  At the same time, there is much less clinical evidence about the opposite 
comparison: addition of endocrine therapy to HER2-targeted agents in MBC, although some EBC 
studies suggest that this may also be beneficial (72).   
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Until recently the most common endocrine agents used in BC clinics were tamoxifen (for pre-
menopausal patients) and aromatase inhibitors (AIs: letrozole, anastrozole and exemestane) for 
post-menopausal patients.  AIs could also be considered for patients of reproductive age after 
ovarian ablation (e.g. with goserelin or oophorectomy).  However, the preferences in selection of 
hormonal agents are likely to change in the view of several recent clinical trials.  First, the FALCON 
study reported that adequately dosed fulvestrant is more effective than an AI for the 1st line ER-
positive MBC (73).  Subsequently, a series of trials showed that the addition of CDK4/6-inhibitors to 
endocrine treatment significantly improves PFS in a metastatic setting (74-76).  None of these trials 
have included HER2-positive patients, but a number of studies combining HER2-targeting with 
fulvestrant, AIs or CDK4/6 inhibitors are already ongoing (PATINA, PATRICIA and monarcHER trials: 
NCT02947685, NCT02448420, NCT02675231).   
3. Key trials supporting current clinical practice 
The results of key trials supporting current clinical practice in HER2-positive MBC are summarised in 
Figure 2. 
3.1. Initial trastuzumab trials 
The pivotal trial by D. Slamon (2001) showed for the first time a significant improvement of both PFS 
and OS after addition of trastuzumab to cytotoxic chemotherapy in HER2+ve MBC (2).  The cytotoxic 
component in this trial included anthracyclines or taxanes.  In addition to the proof of trastuzumab 
efficacy, the trial also highlighted the overlapping cardiotoxicity of trastuzumab and anthracyclines 
(57), paving the way for the wide use of taxanes in combination with trastuzumab in metastatic 
settings.  This also established the practice of monitoring cardiac function during trastuzumab 
treatment.   
Effectiveness of trastuzumab as a monotherapy was demonstrated in a trial conducted by C. Vogel 
with co-authors (2002) (48).  However, the reported PFS was noticeably inferior to the combined 
regimens reported earlier by D. Slamon.  The direct comparison of trastuzumab mono-therapy and 
trastuzumab-taxane combination could be derived from the two trials reported by K. Inoue (2010) 
and P. Hamberg (HERTAX trial) (49, 50).  These trials have a very similar design and report similar 
findings.  For ethical reasons, it was not possible to randomly withdraw cytotoxic treatment from 
MBC patients.  So, the comparison was designed as a randomisation between simultaneous and 
sequential administration of cytotoxics.  In the simultaneous arms, the taxanes were added to 
trastuzumab starting from the beginning of the treatment.  In the sequential arms, the taxanes were 
added only after progression on trastuzumab alone.  In both trials the PFS in the trastuzumab-alone 
phase was markedly shorter than PFS in the trastuzumab-taxane combination.  Moreover, the delay 
in adding cytotoxic treatment significantly reduced OS in both trails.  These trials convincingly show 
that trastuzumab monotherapy may only be reserved for the patients who are not suitable for 
combined regimens.   
3.2. Dual-block by trastuzumab with pertuzumab: CLEOPATRA 
Further progress in treatment of HER2-positive MBC was linked to the development of “horizontal 
dual-blockade”.  A phase III CLEOPATRA trial randomised 808 patients to either the standard 
trastuzumab-taxane arm or the new pertuzumab-trastuzumab-taxane combination.  The addition of 
pertuzumab led to statistically and clinically significant improvements in both PFS and OS.  In 
particular, the median overall survival was extended by more than a year and reached in excess of 
4.5 years (32).  These results are as yet unsurpassed in HER2-positive MBC (if patients are not 
selected by hormonal receptor level);  thus, the CLEOPATRA regimen has substituted trastuzumab-
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taxane combination as the treatment of choice in 1st line metastatic treatment.  At the same time, it 
is worth noting that only ~10% of CLEOPATRA patients were previously exposed to trastuzumab (13, 
77) and a recent PHEREXA trial reported much smaller benefit from addition of pertuzumab to 
trastuzumab-exposed MBC patients in 2nd line treatment (78).   
3.3. Key trials with trastuzumab-emtansine: TH3RESA, EMILIA and MARIANNE 
Effectiveness of trastuzumab-emtansine (T-DM1) has been shown in a series of phase III trials, which 
spanned line1 (MARIANNE), line 2 (EMILIA) and later lines (TH3RESA).  EMILIA and TH3RESA 
demonstrated superiority of T-DM1 over lapatinib + capecitabine and over physician’s choice in 
trastuzumab-exposed patients (43-46).  This shifted the lapatinib + capecitabine combination to 3rd 
line, while T-DM1 has been accepted as the 2nd line treatment of choice.   
The 1st line MARIANNE study compared T-DM1 (+/- pertuzumab) with trastuzumab-taxane 
combination (which was the 1st line treatment of choice at the time of the study design).  T-DM1 was 
non-inferior to trastuzumab-taxane and showed a better safety profile (42).  No trial yet makes a 
direct comparison between T-DM1 and CLEOPATRA protocols.  It could be noted that MARIANNE 
enrolled more patients exposed to trastuzumab than CLEOPATRA (~30% and ~10% respectively) (13, 
77).  However, in view of the clear superiority of CLEOPATRA protocol over trastuzumab-taxane, T-
DM1 remains reserved for 2nd line treatment (although there is no data about T-DM1 efficiency in 
pertuzumab-exposed patients).   
3.4. Selected lapatinib trials 
Different lapatinib-containing combinations were tested in different metastatic settings.  Adding 
lapatinib to chemotherapy significantly improves PFS and OS in 1st and 2nd lines of treatment (Guan-
2013 and EGF00151 studies respectively)(33, 34, 79).  However, a direct comparison in the 1st-line 
treatment showed that lapatinib-taxanes combination has lower efficacy and higher toxicity than 
combination of taxanes with trastuzumab (MA-31 study) (35).  Similarly, despite the proven activity 
of the lapatinib-capecitabine protocol in the 2nd line (EGF00151 study)(34, 79), this combination was 
inferior to T-DM1 in EMILIA trial (43, 46).  Thus, currently lapatinib is reserved for 3rd and later lines 
of treatment.  Utility of lapatinib for patients with brain metastases will be discussed later in section 
5.2.  Importantly, lapatinib is more effective in combination with trastuzumab (the “vertical dual 
blockade”) than taken alone, even in trastuzumab-exposed patients (see EGF104900 and 
ALTERNATIVE trials on Figures 2 and 3)(36, 37, 80).  This is in agreement with other studies 
confirming efficacy of trastuzumab beyond progression (63, 81).   
4. Current consensus guidelines 
Initial HER2-targeting clinical practices were shaped by trials that demonstrated effectiveness of 
adding trastuzumab or lapatinib to chemotherapy in HER2-positive MBC (2, 33).  It was also 
established that HER2-targeting should continue beyond progression through multiple lines of 
treatment (63, 81).  Thus, the general consensus at the time was that trastuzumab + taxanes could 
be considered as the 1st line treatment of choice (58, 82), followed by lapatinib- and capecitabine- 
containing combinations in 2nd line (34).  Overall, this practice was adopted from the time of the 
pivotal trial of D. Slamon in 2001 (2) until the recent development of the horizontal dual-blockade 
(trastuzumab+pertuzumab) and T-DM1.  The first results of a large T-DM1 trial in HER2-positive MBC 
(EMILIA PFS results) were published in 2012 (43).  Similarly, the results of TH3RESA, MARIANNE and 
CLEOPATRA were published between 2014 and 2017 (32, 42, 44, 45).  These trials called for a 
reassessment of previous clinical practices and led to updates in a number of guidelines released by 
expert panels around the world.  The new consensus was set by the ASCO guidelines of 2014 (69), 
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which was broadly followed by a number of other expert panels, including NCCN, ESMO, AGO and 
SEOM, to mention just a few within the last 3 years (13-15, 77, 83-85).  The most commonly 
supported sequencing is summarised in Table 1.  The guidelines agree that (i) dual-blockade with 
trastuzumab+pertuzumab is the preferred regimen for 1st line treatment; (ii) T-DM1 is the 2nd line 
treatment of choice, and (iii) addition of lapatinib may be considered in the later lines.  Pertuzumab-
containing regimens and T-DM1 should also be considered in later lines for the patients, who have 
not received them earlier.  Along with the current consensus, the guidelines highlight that the fast 
and simultaneous development of new HER2-targeted agents lead us to a shortage of evidence 
regarding the use of these agents.  Thus, more data is needed about the efficacy of trastuzumab-
pertuzumab dual-block in trastuzumab-exposed patients.  There is no data yet about efficacy of T-
DM1 on pertuzumab-exposed patients or about the performance of lapatinib- and capecitabine- 
containing regimens on patients pre-treated with T-DM1.   
5. Remaining questions 
In addition to the shortage of data about novel pertuzumab and TDM1 containing regimens, there is 
a list of other questions, which need to be further studied to improve treatment of HER2-positive 
MBC.  These questions include (i) use of hormonal therapy in triple-positive breast cancers, (ii) 
treatment of brain metastases, (iii) assessment and conversion of HER2 expression in metastatic 
lesions, (vi) duration of treatment for metastatic patients with stable and complete response, (v) 
shortage of evidence about cancers resistant to adjuvant treatment and (vi) treatment adjustments 
for elderly patients.  The first two questions are of special importance in this list because they 
immediately affect treatment decisions for a large proportion of HER2-positive MBC patients.   
5.1. Treatment of triple-positive breast cancer 
More than 50% of HER2-positive tumours also express oestrogen receptors (66).  These tumours are 
being increasingly recognised as a distinct group of breast cancers: “Triple Positive Breast Cancer” 
(TPBC) (68, 86, 87), whose unique biology is shaped by a complex interplay of HER2 and ER signalling 
(88-91).  Optimal management of TPBC lies on the border between endocrine and HER2-targeted 
treatments.  However, till recently, HER2-positive tumours have usually been excluded from 
endocrine trials, and studies of HER2-targeted agents often reported results without splitting them 
into ER-positive and ER-negative subgroups.  So far, only a limited number of trials focused on 
metastatic TPBC patients (Fig 3).  Three trials (TANDEM, EGF30008 and ELECTRA) showed that 
addition of HER2-targeting to endocrine treatment significantly prolongs PFS, although the OS 
improvements in these trials did not reach statistical significance (70, 71, 92, 93).  No randomised 
study has yet performed the opposite comparison: the addition of endocrine treatment to HER2-
targeting agents.  However, a retrospective analysis suggests that this may improve the results of 
treatment (72).  Endocrine treatment has low toxicity, and multiple lines of evidence suggest that 
ER-positive tumours may have inferior response to cytotoxic treatment (94, 95).  Taken together, 
these data justify addition of endocrine treatment whenever possible for ER-positive breast cancer, 
which led to the current ASCO and ESMO recommendations to add endocrine agents to the 
treatment plan for most TPBC patients in metastatic setting.  Addition of the hormonal agents to 
HER2-targeted treatment is recommended after completion of cytotoxic chemotherapy (13, 69, 77).  
Importantly, the guidelines emphasise that addition of endocrine therapy is not based on direct 
evidence.  Also, they provide no reason why endocrine therapy should be delayed until completion 
of cytotoxic treatment.   
The shortage of evidence about TPBC patients is being addressed by several recent and ongoing 
clinical trials summarised in Figure 3 and Table 2.  The recently reported PERTAIN trial was designed 
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to evaluate the effect of horizontal dual-blockade in metastatic TPBC (96).  The control arm included 
trastuzumab + aromatase inhibitor while the experimental arm added pertuzumab to the 
combination.  Induction chemotherapy with taxanes prior the aromatase inhibitor was permitted at 
the discretion of the investigator (and was applied in ~50% cases in both arms).  The analysis showed 
a significant increase in PFS after addition of pertuzumab.  However, PERTAIN’s results may also be 
considered in a wider context.  It was the first controlled trial that reported results of combining 
HER2-targeting, cytotoxic and hormonal treatment at the same time – and the effect of such 
combination in both PERTAIN arms was unprecedented.  Thus, median PFS in the experimental arm 
exceeded 2 years (27.1 months), which is an exceptional result for a metastatic cancer.  Although 
PFS in the control PERTAIN’s arm was “just” 15.1 month, it was comparable to PFSs reported in 
experimental arms by MARIANNE and CLEOPATRA (14.1 and 18.5 months) despite the fact that only 
half of PERTAIN patients received taxanes.  Another interesting observation about PERTAIN was the 
very fact that investigators opted not to include taxanes in nearly 50% of cases, even though it was 
permitted by the protocol.  The treatment sub-groups analysis (for patients with and without 
taxanes) and overall survival data of PERTAIN trial are awaited with interest.   
The second recently reported metastatic TPBC trial is ALTERNATIVE (37).  The study enrolled TPBC 
patients progressing on a (neo)adjuvant / 1st line trastuzumab + chemotherapy regimen.  The 
treatment included three arms: trastuzumab vs. lapatinib vs. trastuzumab + lapatinib.  Aromatase 
inhibitors were added in each arm.  Patients intended for cytotoxic chemotherapy were excluded 
from this trial.  The vertical dual blockade (trastuzumab + lapatinib combination) showed superior 
PFS as compared with lapatinib or trastuzumab alone (11, 8.3 and 5.7 months respectively).  Again, 
despite the absence of cytotoxic treatment in this trial, the 11 months median PFS achieved in 
trastuzumab+lapatinib+AI arm was amongst the best reported in HER2-positive 2nd line trials, such as 
EMILIA (9.6 months PFS for T-DM1) or PHEREXA (11.1 months for horizontal dual-block + taxanes) 
(43, 78)).  It is not yet clear whether the exceptional PFS results reported by PERTAIN and 
ALTERNATIVE reflect the favourable intrinsic properties of TPBC or the good response to combined 
HER2- and ER- targeting, and these trials have not yet reported the overall survival data.  However, 
these trials already provide interesting and encouraging data about new treatments and outcomes 
in metastatic TPBC.   
A significant progress has been made over the recent years in treatment of metastatic ER-positive 
HER2-negative breast cancer: fulvestrant (500mg) has been promoted to 1st line metastatic 
hormonal treatment (73) and CDK4/6 inhibitors have been established as a standard addition to 
endocrine agents (97).  This progress triggered a series of trials testing whether these new 
approaches could be beneficial for TPBC patients (Table 2).  Thus, phase II PATRICIA and monarcHER 
trials study addition of CDK4/6 inhibitors to trastuzumab (with or without hormonal treatment) in 
patients progressing after previous trastuzumab-containing metastatic regimens.  Phase III PATINA 
trial studies addition of CDK4/6 inhibitors to HER2-targeted agents in 1st line metastatic treatment 
(with or without hormonal therapy).  Two other ongoing trials compare endocrine and cytotoxic 
therapies in combination with HER2 targeting in metastatic TPBC (DETECT-V and SYSUCC-002 trials, 
see details in Table 2).  All these trials are currently enrolling patients.  The results are expected 
between 2018 and 2024.   
Taken together, the recently reported and ongoing trials in metastatic TPBC will provide evidence-to 
support new treatment standards for this group of patients.  Finally, it could be noted that most 
metastatic TPBC patients were exposed to previous endocrine treatments in a (neo)adjuvant setting 
and/or in previous metastatic lines.  Thus, testing for activating mutations in ligand-binding domain 
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of oestrogen receptor may be helpful for rational selection of the endocrine component of their 
treatment (98).  
5.2. Targeted treatment of brain metastases 
Brain metastases (BM) have a distinct biology and poor prognosis (99, 100).  Currently, symptomatic 
BM are reported in 20% to 40% of HER2-positive MBC (101, 102).  Additionally, up to 10% of patients 
may have asymptomatic BM detectable on autopsy (100).  Incidence of BM is significantly higher in 
ER-negative than in ER-positive disease (99).  Treatment of BM is based on radiotherapy and surgery, 
supported by systemic therapies based on cytotoxic and targeted agents (103-105).  The backbone 
systemic therapy could be combined with additional medication (such as corticosteroids and anti-
epileptic drugs) that is beyond the scope of this review (106).  Paradoxically, treatment with 
trastuzumab increases incidence of brain metastases (107-110) while prolonging the time to BM 
(110) and overall survival of patients with BM (108, 111).  This is commonly explained by 
trastuzumab’s success in suppressing extracranial metastatic sites, which allows time for brain 
metastases to develop and manifest clinically.  Importantly, while achieving good extra-cranial 
control, trastuzumab has limited effect on brain metastases themselves because of its poor 
permeability through the blood-brain-barrier (BBB).  Thus, under conditions of unimpaired BBB, 
trastuzumab’s concentration in cerebrospinal fluid could be 420 times below its concentration in 
serum; even when BBB is compromised by irradiation the concentration of trastuzumab in brain is 
still about 50 times lower than in the blood (112).  In contrast, small-molecule TKIs, like lapatinib, 
penetrate BBB much better (113).  This raised expectations about a possible special role for TKIs in 
BM treatment and encouraged a number of small trials evaluating effect of lapatinib on BM in 
heavily pre-treated HER2-positive MBC patients (114).  In these trials lapatinib alone showed low 
CNS response rates (2-6%) and low PFS (up to 3 months).  However, when lapatinib was combined 
with capecitabine, the objective response rates rose to 18-38% and PFS to ~5 months.  For 
comparison, CNS PFS reported for cytotoxic chemotherapies alone did not exceed 4 month at the 
time (114).  Taken together, these trials suggested some CNS benefit from addition of lapatinib, 
although of a limited clinical significance in pre-treated population.  In 2013 a small single-arm open-
label trial tested lapatinib+capecitabine combination on patients with previously untreated brain 
metastases (LANDSCAPE trial).  It reported 66% CNS ORR and median PFS of 5.5 months (115).  
Excellent ORR in LANDSCAPE trial was reflected in some guidelines, including ASCO-2014 and EANO-
2017 (104, 105).  However, a later CEREBEL trial failed to show superiority of lapatinib+capecitabine 
over trastuzumab in preventing BM (38).  Although interpretation of the CEREBEL trial is complicated 
by the unexpectedly low rates of BM (3-5%), this trial brought some caution toward the 
lapatinib+capecitabine regimen.  More importantly, a sub-analysis of EMILIA trial directly showed 
that T-DM1 provides better OS than lapatinib+capecitabine in patients with BM (116).  Similarly, 
trastuzumab and/or pertuzumab trials showed improvement in overall survival for patients with BM 
(111, 117), despite the low penetrance of BBB for these drugs.  This is commonly explained by the 
importance of extracranial control in patients with BM.  Building on this evidence, the most recent 
ABC-3 guideline from ESO-ESMO does not recommend a change of systemic treatment for patients 
with BM, providing stable extracranial disease (13, 77).  A trastuzumab-containing regimen is still 
essential for patients with BM because of its contribution to extracranial control.  However, 
considering the low penetrance of BBB for trastuzumab, patients with BM may be encouraged to 
participate in clinical trials (85, 105).  Trials of new TKIs, such as neratinib, are underway (118).  
Future trials combining small molecules and antibody-based agents may also be expected, as well as 
the trials of new methods to increase BBB permeability (119).   
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6. Therapies under development 
The HER2-targeted treatments developed over the last 20 years converted the unfavourable natural 
history of HER2-positive BC into favourable clinical outcomes.  At the same time, the metastatic 
disease still remains incurable for most patients.  The innate and acquired resistance to existing 
therapies requires development of novel agents and strategies.  The range of new therapies that are 
currently under development for HER2-positive MBC include (i) new TKIs targeting ERBB receptors 
and their down-stream signalling, (ii) inhibitors of cell cycle, HSP90 and angiogenesis, (iii) HER2-
targeted drug delivery and (iv) new antibodies and immunotherapy aimed at HER2-positive BC.   
6.1. New ERBB-targeting TKIs  
Neratinib is classified as a pan-ERBB TKI because it binds and irreversibly inhibits all ERBB receptors 
except HER3 (118, 120).  On the basis of ExteNET study, neratinib has been recently approved by the 
FDA for extended post-trastuzumab adjuvant treatment (121).  However, neratinib yet failed to 
show superiority over comparators in metastatic settings.  Comparison of neratininb with 
trastuzumab (both in combination with taxanes) in 1st line treatment was performed by NEfERT trial, 
which reported identical PFS in both arms (12.9 months) and much higher toxicity in the neratinib 
arm (grade 3 diarrhoea developed in up to 30% of patients) (122).  In a 2nd line trial that compared 
neratinib monotherapy against the combination of lapatinib+capecitabine, the neratinib arm 
showed shorter PFS and OS than the combination (PFS 4.5 vs 6.8 and OS 19.7 vs 23.6 months 
respectively, differences between arms are not significant) (123).  At the same time, a sub-analysis of 
NEfERT-T trial showed that neratinib was more effective against brain metastases (relative risk of 
CNS recurrences 0.48, p = 0.002).  Another pan-ERBB TKI, afatinib, was tested in several breast 
cancer trials, and has progressed to a phase III trial in the 1st line metastatic setting (LUX-Breast 1).  
However, this trial was stopped after an interim assessment showed that afatinib outcomes were 
less favourable than trastuzumab (124).  Neither neratinib nor afatinib are currently approved for 
treatment of HER2-positive MBC outside of clinical trials (125), although new trials of neratinib may 
be expected in patients with brain metastases.   
As an alternative to pan-ERBB inhibitors, a selective HER2-specific TKI was developed by Array 
BioPharma (Tucatinib, formerly known as ONT-380 or ARRY-380).  It was expected to reduce the off-
target effects and high toxicity common for dual-  and pan- ERBB inhibitors.  In a phase I trial, 
Tucatinib showed promising efficacy and safety profile (126).  It also showed capacity to penetrate 
the BBB and some promising results in patients with brain metastases (127).  In view of these phase I 
results, a phase II trial has been recently initiated, which combines tucatinib with trastuzumab and 
capecitabine in HER2-positive MBC (HER2CLIMB, NCT02614794).  Another recently initialled 
tucatinib trial combines it with CDK4/6 and aromatase inhibitors in metastatic TPBC patients 
(NCT03054363).  The results of these trials are awaited with interest.   
6.2. PI3K and mTOR inhibitors 
PI3K and mTOR are key components in signalling downstream of HER2 (Figure 1B).  The m-TOR 
inhibitor everolimus has been extensively studied in breast cancer, and it is approved for treatment 
of ER-positive HER2-negative BC on the basis of BOLERO-2 trial (128).  However, it showed less 
encouraging results in two large phase III trials in HER2-positive MBC (BOLERO-1 and BOLERO-3).  
BOLERO-1, which studied addition of everolimus to trastuzumab+taxanes in 1st line metastatic 
treatment, reported that everolimus was associated with increased toxicity without any 
improvement in either PFS or OS (129, 130).  BOLERO-3 tested addition of everolimus to 
trastuzumab+vinorelbine in 2nd line metastatic treatment for patients previously exposed to 
trastuzumab and taxanes.  The addition of everolimus in the BOLERO-3 led to a statistically 
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significant improvement of PFS (131).  However, numerically the median PFS was prolonged by less 
than 2 months (7.0 vs 5.8 months) and there was no improvement in OS (132).  A joint analysis of 
the BOLERO-1 and BOLERO-3 was conducted in search for biomarkers to select patients benefiting 
most from treatment with everolimus.  It showed that somatic mutations in the PI3K pathway 
(PIK3CA, PTEN and AKT1 genes) could be used to predict response, and that everolimus benefit was 
mainly limited to ER-negative patients (133).  Several PI3K-targeted TKIs, which also have been 
previously studied in ER-positive HER2-negative BC, are currently at early stages of testing in HER2-
positive disease (including buparlisib (134), alpelisib (135), taselisib - NCT02390427 and pictilisib – 
NCT00960960).  Like everolimus, none of these PI3K inhibitors is yet recommended for HER2+ve 
patients outside of clinical trials.  However, they may be used in future personalised treatment of 
HER2-positive MBC if companion biomarkers are developed to select responsive patients.   
6.3. CDK4/6 inhibitors 
CDK4 and CDK6 are partners of Cyclin D1, the key cell cycle regulator controlling G1-S transition.  
Activated by Cyclin D1, CDKs 4/6 phosphorylate RB protein, which in turn releases E2F from RB-E2F 
complexes leading to activation of Cyclin E and downstream cell cycle machinery (Fig 1B) (136).  
Cyclin D1 is frequently amplified in human cancers, including breast cancer (137).  Surprisingly, 
despite the central role of Cyclin D1 in cell cycle regulation, mice lacking Cyclin D1 are viable and 
resistant to HER2(neu)-induced breast cancers (but not to breast cancers induced by MYC) (138).  
HER2-amlpified breast cancer cell lines are among the most sensitive to CDK4/6 inhibition (74).  
Along with the involvement in HER2-dependent carcinogenesis, Cyclin D1 also plays a key role in 
signalling downstream of oestrogen receptor (139).  These molecular findings triggered interest in 
CDK4/6 inhibitors for breast cancer treatment, culminating in several recently published large phase 
III clinical trials (PALOMA-2/3, MONALEESA-2 and MONARCH-2) that tested addition of different 
CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib, respectively) to hormonal therapies in ER-
positive HER2-negative MBC (75, 97, 140, 141).  The success of these trials led to regulatory 
approvals and supported a wave of interest in CDK4/6 inhibitors for treatment of HER2-positive 
disease.  Several ongoing CDK4/6 trials in HER2-positive MBC were discussed in the TPBC section of 
this review (PATRICIA, monarcHER and PATINA, see Table 2).  Notably, one of the PATRICIA arms also 
includes ER-negative patients.  It was also reported that abemaciclib has good CNS penetration, 
showing similar concentrations in the plasma and brain (142).  Importantly, the effect of CDK4/6 
inhibitors requires intact RB protein expression (143).  Thus, RB loss (and other RB mutations) should 
be monitored before treatment with CDK4/6 inhibitors and after progression on treatment.  At 
present, CDK4/6 inhibition is perceived as one of the most promising new directions in the 
treatment of HER2-positive MBC, which may soon be used in clinical practice (at least in TPBC 
patients) (144).   
6.4. Inhibitors of HSP90 and angiogenesis 
Experimental studies suggested a potential role for HSP90, angiogenesis and topoisomerase 
inhibitors in treatment of different types of cancer.  However, clinical trials have not yet justified 
including these drugs into routine clinical practice in HER2-positive MBC.   
HSP90 is a chaperon protein, which is required for proper folding and function of hundreds of its 
client proteins (145) including HER2 and its key downstream targets (146).  Preclinical studies 
reported anti-tumour activity of HSP90 inhibitors on a wide range of BC cells, with HER2-positive cell 
lines being particularly sensitive (147).  In 2011 a phase II clinical trial studied effect of an HSP90 
inhibitor tanespimycin on 31 HER2+ve MBC patients who previously progressed on trastuzumab 
(148).  It reported objective responses to the tanespimycin+trastuzumab combination in 22% of the 
patients with median PFS of 6 months and median OS of 17 months.  While this was a positive result, 
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the efficiency of tanespimycin+trastuzumab looked modest in comparison to trastuzumab-
emtansine reported shortly afterwards (EMILIA trial first reported in 2012: PFS 9.6 months and OS 
30.9 month) (43).  Another HSP90 inhibitor showed limited efficacy in HER2-positive MBC in a phase 
II trial reported in 2013 (149).  No further clinical trials of HSP90 inhibitors were reported in HER2+ve 
MBC since then.  However, the overall interest and experimental studies of HSP90 are continuing, 
with focus on biological complexity of HSP90 functions in cancer (145, 150, 151).   
Similarly, there were attempts to inhibit angiogenesis in HER2+ve metastatic cancer.  Angiogenesis is 
highly specific for tumour tissue in adults (152).  HER2 overexpression stimulates VEGF expression in 
breast cancer (153), potentially leading to poorer clinical outcomes (154).  Phase I and II trials 
showed that inhibitors of angiogenesis (such as VEGF inhibitor bevacizumab) may have effect on 
some HER2-positive MBC (155).  However, a phase III clinical trial of bevacizumab in HER2-positive 
MBC failed to detect an improvement in PFS in 1st line treatment (AVEREL trial)(156), which was 
consistent with an unsuccessful adjuvant trial in HER-positive EBC (BETH trial) (157).  Since 2010, the 
FDA does not approve bevacizumab for any form of breast cancer.  The current studies of 
angiogenesis inhibitors in breast tumours are focused on the search for the sub-set of tumours that 
may be responsive to this class of drugs (158, 159).   
6.5. HER2-targeted drug delivery and immunotherapies 
The success of T-DM1 stimulated development of other HER2-targeted antibody-drug-conjugates 
(ADC).  The main directions in development of new ADC include (i) new targeting antibodies, (ii) new 
conjugated drugs and (iii) increasing the drug-to-antibody ratio.  Thus, DS-8201 is a conjugate of 
trastuzumab with a topoisomerase-1 inhibitor (160).  Its development progressed to a phase I clinical 
trial, which confirmed safety and potential efficacy in T-DM1-exposed patients (161).  Another novel 
ADC is XMT-1522.  Its antibody part targets a new epitope on HER2, thus avoiding potential 
competition for epitopes with trastuzumab or pertuzumab if used in combination.  Moreover, each 
XMT-1522 antibody is conjugated with 15 molecules of a proprietary cytotoxic component 
auristatin.  XMT-1522 showed significantly higher potency than T-DM1 in preclinical models (162).  
Currently it is being tested in a phase I clinical trial (NCT02952729).  
An alternative approach to HER-2 targeted drug delivery was tested by an antibody-conjugated 
liposomal doxorubicin formulation called MM-302.  It delivered drug to tumour in liposomes tagged 
with anti-HER2 antibodies.  The intention was to expand doxorubicin therapeutic range by avoiding 
its cardiotoxicity.  A recent phase II trial (HERMIONE) compared the combination of trastuzumab 
with MM-302 against a combination of trastuzumab with cytotoxic chemotherapy of physician 
choice in heavily pre-treated HER2-positive MBC patients (163).  MM-302 was well tolerated.  
However, the trial has been terminated after an interim review showed no efficacy benefit over the 
comparator.  Another new strategy is non-antibody targeting.  Thus, S. Pallerla with co-authors 
designed a HER2-targeted doxorubicin-peptidomimetic conjugate (164).  The targeting is achieved by 
a short peptide that selectively binds to HER2.  The compound is still in an early preclinical phase.  An 
interesting approach was reported by X. Kang with co-authors, who conjugated trastuzumab with 
gold nanoparticles, which allowed HER2-targeted photothermal tumour destruction (165).  
Potentially, this method avoids any chemotherapy-associated toxicity.  However, the studies are also 
still at a preclinical phase (testing on xenografts).   
Finally, it is well established that immune mechanisms may contribute to response to trastuzumab 
(see Section 2.1.1) (22, 23).  A new antibody, magretuximab, has been designed to enhance the 
antibody-dependent cell-mediated cytotoxicity against HER2-positive tumour cells.  Its Fab region 
targets the same epitope as trastuzumab.  However, its Fc region was modified to increase affinity to 
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activating Fc-receptors on NK-cells and macrophages.  Magretuximab was well tolerated and showed 
promising efficacy as a monotherapy in phase I clinical trial (166).  A phase III trial, SOPHIA, is testing 
a combination of magretuximab + cytotoxic chemotherapy in trastuzumab-exposed MBC patients 
(167).  An alternative approach is used in ertumaxomab: an engineered multi-functional antibody 
that simultaneously binds HER2, CD3 and the Fc-gamma-receptors.  Potentially, this might promote 
immune response by bringing together the tumour cell, T-cell and accessory immune cells at the 
same time.  So far, ertumaxomab has been tested in two phase-I clinical trials that reported 
encouraging safety and efficacy (168, 169).  Other immunotherapy approaches that already reached 
at least phase I-II trials include immune checkpoints inhibitors (PANACEA and KATE2 trials: 
NCT02129556, NCT02924883), T-cell therapies (170) and vaccines (171).  Overall, despite still being 
at early stages of development, the new HER2-targeted drug delivery systems and immunotherapies 
show promise and may extend our armamentarium for treating HER2-positive MBC.   
7. Conclusions 
High expression or amplification of HER2 defines a distinct group of breast cancers.  20 years ago it 
was considered as an intrinsically aggressive subtype associated with poor prognosis (1).  However, 
the tumours dependence on HER2 has also provided a target for treatments, which dramatically 
changed the outcomes for this type of disease.  Now HER2-positive breast cancer is considered as a 
favourable subtype (3-6) with about 70% of EBC patients reaching 10-year disease-free survival after 
the current HER2-targeted adjuvant treatments (172).  While the metastatic HER2-positive BC 
remains incurable, HER2-targeting significantly prolonged live of these patients too, with median 
overall survival exceeding 4 years in recent clinical trials (32, 42).  HER2-targeted agents currently 
approved for metastatic breast cancer include trastuzumab, pertuzumab, trastuzumab-emtansine 
and lapatinib.  They are used in different combinations with each other and with other 
chemotherapeutic agents.  The recent progress in treatment of HER2-positive MBC was achieved by 
the development of horizontal dual blockade (pertuzumab + trastuzumab) (32) and by HER2-
targeted drug delivery (trastuzumab-emtansine) (42).  The current studies focus on (i) accumulating 
new evidence about recently established treatment regimens, (ii) treatment stratification by 
expression of oestrogen receptors, (iii) treatment of brain metastases, (iv) development of new tools 
for HER2-targeting (new TKIs, antibodies, antibody-drug conjugates and immunotherapies) and on 
(v) targeting pathways downstream of HER2 (including TKIs and CDK4/6 inhibitors).  Future therapies 
will be based on molecular profiling and companion diagnostics to allow monitoring and rational 
selection of targeted treatments for individual patients.   
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Tables 
Table 1 
Current consensus sequencing of metastatic treatment in HER2-positive MBC 
1st line • Trastuzumab + Pertuzumab + Taxanes  
(vinorelbine may be considered instead of taxanes) 
• Trastuzumab-emtansine (T-DM1) may be considered if patient is not suitable for 
the above or in case of a fast progression on/after adjuvant Trastuzumab 
2nd line • Trastuzumab-emtansine (T-DM1) 
• Trastuzumab + Pertuzumab + Cytotoxic chemotherapy (taxanes, vinorelbine or 
capecitabine) may be considered if not exposed to Pertuzumab previously 
3rd line • Regimens currently recommended for 1st or 2nd line should be considered for the 
later lines, if not used previously 
• Trastuzumab or Lapatinib + Cytotoxic chemotherapy (including vinorelbine, 
capecitabine, gemcitabine, eribulin and others, if not used previously) 
• Trastuzumab + Lapatinib if not suitable for cytotoxic chemotherapy 
 
Notes:  
1) Addition of endocrine therapy to HER2-targeted agents should be considered at any line after 
completion of cytotoxic chemotherapy in ER-positive patients  
2) Based on ASCO 2014 (69), NCCN 2017 (14), ESMO-ABC3 2017 (13,77), AGO 2015 (85) and SEOM 
2015-2017 (15,83,84) guidelines  
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Table 2 
Ongoing clinical trials in metastatic TPBC 
PATRICIA 
NCT02448420 
Phase II 
Postmenopausal patients exposed to trastuzumab in previous metastatic setting 
3 arms:  
• ER negative, HER2 positive patients: palbociclib + trastuzumab 
• ER positive, HER2 positive patients: palbociclib + trastuzumab 
• ER positive, HER2 positive patients: palbociclib + trastuzumab + letrozole 
Expected completion: 2019 
monarcHER 
NCT02675231 
Phase II 
TPBC after at least two HER2-targeted therapies for advanced disease 
3 arms: 
• Abemaciclib + Trastuzumab + Fulvestrant 
• Abemaciclib + Trastuzumab 
• Trastuzumab + Chemotherapy of Physician Choice 
Expected completion: 2018-2019 
PATINA 
NCT02947685 
Phase III 
1-st line metastatic TPBC patients 
2 arms: 
• Palbociclib + Anti-HER2 Therapy + Endocrine Therapy 
• Anti-HER2 Therapy + Endocrine Therapy 
Induction cytotoxic chemotherapy is allowed prior randomisation 
Expected completion: 2020-2024 
DETECT-V / 
CHEVENDO 
NCT02344472 
Phase III 
TPBC patients with up to 2 prior therapies for the metastatic disease 
2 arms:  
• Trastuzumab + Pertuzumab + Cytotoxic chemotherapy 
• Trastuzumab + Pertuzumab + Endocrine therapy 
Quality of life and adverse effects as a primary outcome 
Expected completion: 2021 
SYSUCC-002 
NCT01950182 
Phase III 
1-st line metastatic TPBC patients 
2 arms:  
• Trastuzumab + Cytotoxic chemotherapy 
• Trastuzumab + Endocrine therapy 
Expected completion: 2018 
NCT03054363 
Phase Ib - II 
Tucatinib in combination with Palbociclib and Letrozole for 1st or 2nd line 
metastatic TPBC 
In 2017, the study is not yet open for participant recruitment 
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Figures notes 
Figure 1 
Title 
HER2 signalling 
Notes 
A: HER2 hetero-dimerization and HER2 targeting.  B: Signalling downstream of HER2 and its targeting 
Figure 2 
Title 
Selected trials supporting current practices in HER2-positive MBC  
Notes 
T = Trastuzumab, P = Pertuzumab, L = Lapatinib, Tx = Taxanes, Cp = Capecitabine, Ac = 
Anthracyclines, Ph Ch = Physician Choice.   
a: Difference between arms is not significant.   
b: In the sequential arm Tx is added after progression on T alone.  PFS is shown for T alone phase 
only.  
c: OS is in favour of T + Tx, median OS not reached.   
d: OS not reported.   
e: After 3 T-containing lines on average.   
f: After at least 2 metastatic lines.   
Median PFS and OS are indicated in months.   
Figure 3 
Title 
TPBC trials 
Notes 
T = Trastuzumab, P = Pertuzumab, L = Lapatinib, AI = Aromatase Inhibitor.   
a: Mixed 1st and later lines; PFS and OS for patients with centrally confirmed ER.   
b: OS trend not significant.   
c: OS not reported.   
Median PFS and OS are indicated in months.   
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